Inloggad som:
VEX-AZA
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
VEX-AZA
VEX-AZA: Behandling av VEXAS-syndrom med Azacitidin, en studie om säkerheten och effekten av behandling av VEXAS med Azacitidin
A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Patients with VEXAS Syndrome
Skånes universitetssjukhus / Hematologisk vård
A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Patients with VEXAS Syndrome
Mer information om studien för vårdgivare
Participants must possess one of the currently described UBA1 mutations in their bone marrow cells with a variant allele frequency (VAF) > 10% evaluated with targeted next generation sequencing (NGS). For more info, see link
Patients having received prior therapy with hypomethylating agents (i.e., Azacitidine, Decitabine), patients having received or is planned to receive alloHSCT, patients with active cancer requiring treatment
Behandling
Fas 2
Kurativ
Ej tillämpbar
Akademisk
Studien ändrades senast: (2025-09-30)